DUBLIN--(BUSINESS WIRE)--The "Global Gaucher Disease Treatment Market Outlook 2027" report has been added to ResearchAndMarkets.com's offering.
Gaucher disease (GD) refers to the accumulation of glucocerebroside in cells and certain organs leading to the enlargement of the liver and spleen. The genetic disorder is caused by a hereditary deficiency of the enzyme glucocerebrosidase and is characterized by bruising, fatigue, anemia and low blood platelet count.
The global Gaucher disease market is anticipated to record a CAGR of around 3% over the forecast period, i.e. 2019-2026. Factors such as increasing incidences of Gaucher's disease as well as the increasing focus of the pharmaceutical companies on introducing new products that cater to the treatment of Gaucher disease are anticipated to contribute significantly towards the growth of the global Gaucher disease market. Additionally, increasing concern for the growing incidences of Gaucher disease amongst people around the globe, coupled with the growing support and funding of the government of nations and the rising per capita expenditure on healthcare by several nations around the globe are some of the factors anticipated to drive the growth of the global Gaucher disease market.
The global Gaucher disease market consists of various segments that are segmented by product type, by infusion mode, by clinical type, by end user and by region. The product type segment is further sub-divided into enzyme replacement therapy or ERT and substrate replacement therapy or SRT. Out of these, the enzyme replacement therapy segment, which held a market value of around USD 1400 million in the year 2018, is anticipated to grow with a CAGR of around 3% during the forecast period. On the basis of infusion mode, the market is segmented into intravenous infusion and oral. Out of these segments, the intravenous infusion segment is anticipated to hold the largest market share by the end of 2026 and is anticipated to grow with a CAGR of around 3% during the forecast period and reach a value of around USD 1600 million by the end of 2026.
Based on region, the global Gaucher disease market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in Europe, which had accounted for around 28% share in the year 2018, is estimated to witness a CAGR of around 2% during the forecast period and reach a value of around USD 520 million by the end of 2026.
- Protalix Inc.
- Pfizer Inc.
- Actelion Pharmaceuticals Ltd.
Takeda Pharmaceutical Company Limited
Key Topics Covered:
Global Gaucher Disease Market
2. Research Methodology
3. Global Gaucher Disease Market - Executive Summary
4. Global Gaucher Disease Market Overview
4.1. Market Dynamics
4.1.1 Driving Forces
22.214.171.124 Growing Incidence Of Gaucher Disease
126.96.36.199 Increasing Governmental Support And Growing Demand For Enzyme Replacement Therapy For The Treatment Of Rare Diseases
4.1.2 Restraining Factor
188.8.131.52 High Cost Of Product And Therapies
4.1.3 Opportunity Matrix
184.108.40.206 Expansion Of Product Portfolio Especially In Towards Pharmaceutical Products
5. Industry Insights
5.1. Porter's Five Forces Analysis
5.1.1 Bargaining Power Of Supplier
5.1.2 Bargaining Power Of Buyer
5.1.3 Threat Of Substitute
5.1.4 Threat Of New Entrant
5.1.5 Degree Of Competition
5.2. Value Chain Analysis
6. Global Gaucher Disease Market, By Product
7. Global Gaucher Disease Market, By Infusion Modes
8. Global Gaucher Disease Market, By Distribution Channel
9. Global Gaucher Disease Market, By Clinical Type
10. North America Gaucher Disease Market
10.1.1.1 North America Market Analysis, By Product Type
10.1.1.2 North America Market Analysis, By Intake Mode
10.1.1.3 North America Market Analysis, By Clinical Types
10.1.1.4 North America Market Analysis, By End-Users
10.2.1.1 U.S. Market Analysis, By Product Type
10.2.1.2 U.S. Market Analysis, By Intake Mode
10.2.1.3 U.S. Market Analysis, By Clinical Types
10.2.1.4 U.S. Market Analysis, By End-Users
10.3.1.1 Canada Market Analysis, By Product Type
10.3.1.2 Canada Market Analysis, By Intake Mode
10.3.1.3 Canada Market Analysis, By Clinical Types
10.3.1.4 Canada Market Analysis, By End-Users
11. Latin America Gaucher Disease Market
12. Europe Gaucher Disease Market
13. Asia Pacific Gaucher Disease Market
14. Middle East And Africa (MEA) Gaucher Disease Market
15. Company Profiles
15.1. Protalix Biotherapeutics Inc
15.1.1 Company Overview
15.1.2 Financial Performance
15.1.3 Product Portfolio
15.2. Pfizer Inc
15.3. Actelion Pharmaceuticals Ltd
15.4. Sanofi Sa
15.5. Takeda Pharmaceutical Co Ltd
For more information about this report visit https://www.researchandmarkets.com/r/r887i0